The forecast for spending on pharmaceutical benefits in 2025-26, which is just 8 weeks from finalisation, is $5.6 billion higher than it was four years ago, assuming most of that growth will be offset by rebates. This is not to defend the status quo but to encourage accuracy. …
Updated forecast highlights the real risk of relying on these numbers
May 13, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Immutep cancer candidate shows strong median survival in lung cancer as company consider conflicting trial results
July 13, 2026 - - Australian Biotech -
OncoSil Medical establishes scalable Australian production after successful manufacturing validation
July 13, 2026 - - Australian Biotech -
SCENESSE gains Canadian approval offering long term protection for patients with rare disorder
July 13, 2026 - - Australian Biotech -
Patrys and Yale agree revenue share to advance deoxymab platform
July 13, 2026 - - Australian Biotech -
Mesoblast reports strong cell therapy revenue as first year as uptake grows
July 13, 2026 - - Latest News -
What is it with this organisation's obsession with pharmacy and Europe?
July 13, 2026 - - Latest News -
The inevitability of disappointment over a reform process that has devolved into word games
July 12, 2026 - - Latest News